Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025ACS OmegaOpen Access

Hesperetin and Isoliquiritigenin Attenuate the Progression of Diabetic Nephropathy via Inhibition of NF-κB/NLRP3 Pathways in Type 2 Diabetic Rats

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMeenu MeenuUBUzma BanoMMMohd Mujeeb

Discussion

Loading...

Member takes

Overview

Investigative study reveals that hesperetin and isoliquiritigenin improve renal function and inflammation in type 2 diabetic rats, suggesting potential therapeutic roles.

Key Points

  • Hesperetin and isoliquiritigenin significantly improved kidney function in type 2 diabetic rats, reducing markers of renal damage.
  • The study showed decreases in inflammatory and oxidative stress biomarkers, indicating enhanced kidney health after treatment.
  • Administration of hesperetin and isoliquiritigenin involved oral doses over 4 weeks, focusing on their impact on diabetic nephropathy.
  • These findings point to the importance of NLRP3 and NF-κB pathways in managing diabetic kidney disease and highlight potential therapeutic targets.

Cite This Study

Meenu et al. (2025) studied this question.

synapsesocial.com/papers/68c23dc5b210217d6478fa08https://doi.org/10.1021/acsomega.5c02026
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Licoricidin Ameliorates Renal Function via Controlling Stress and Inflammation in Experimental Diabetic Nephropathy Animal Model2025
  2. 2Vitamin D restores redox balance and modulates irisin and spexin expression in a rat model of streptozotocin-induced diabetic nephropathy2025
  3. 3Cinnamic acid ameliorates diabetic nephropathy in rats <i>via</i> Nrf2 activation and inflammation modulation2025 · 2 citations
  4. 4Astragaloside IV reduces diabetic kidney injury by inhibiting the PKC/NOX4/MAPK pathway2025
  5. 5Honokiol attenuates diabetic nephropathy by targeting SIRT3 to suppress mitochondrial ROS-induced pyroptosis2025